Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide plus prednisone, etoposide, and lenalidomide induction followed by bendamustine plus CD20 monoclonal antibody consolidation in elderly or frail relapsed/refractory follicular lymphoma
ChiCTR2200057539Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat, prednisone, etoposide, lenalidomide and bendamustine in follicular lymphoma (FL), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Complete response rate. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
tucidinostatprednisoneetoposidelenalidomidebendamustine
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ChiCTR2200057539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057539.